PharmaEssentia USA Corporation

PharmaEssentia USA Corporation is the U.S. commercial subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator headquartered in Taipei, Taiwan. The U.S. entity is based in Burlington, Massachusetts, and is dedicated to delivering effective new biologics for challenging diseases in hematology, oncology, and immunology.

The company focuses on developing therapies for hematologic diseases and cancers, particularly Myeloproliferative Neoplasms (MPNs) such as Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Its flagship product is BESREMi® (ropeginterferon alfa-2b-njft), which is FDA-approved for adults with polycythemia vera. PharmaEssentia leverages a novel pegylation technology platform to develop its pipeline of treatments.

In June 2026, PharmaEssentia USA Corporation announced the FDA approval and U.S. launch of the BESREMi Pen™ for polycythemia vera, offering a more convenient self-administration option. The parent company, PharmaEssentia Corporation, also recently expanded its North American commercial footprint through the acquisition of Canadian partner FORUS Therapeutics Inc. PharmaEssentia Corporation is publicly traded on the Taiwan Stock Exchange under the ticker symbol TWSE: 6446.